Q2 2025 Key Financial Highlights - Revenue grew by 15% year-over-year in Q2[7] - Net income increased by 120% year-over-year for Q2[7] - Adjusted EBITDA increased by 12% year-over-year for Q2, reaching 22.7% of revenue, aligning with the full-year outlook[7] - The company repurchased 270,061 common shares for $1.8 million, at an average price of $6.79 per share[7] Operational Performance - Vent patient growth was robust, with an 11% year-over-year increase in Q2 and a 3% sequential increase from Q1[7] - Sleep therapy patients increased significantly, up 51% year-over-year and 15% sequentially in Q2; new sleep patient starts were up 72% year-over-year, and sleep resupply patient count was up 25% year-over-year and 10% sequentially[7] Financial Position and Strategy - The company completed the strategic acquisition of Lehan's Medical Equipment on July 1, 2025, expected to contribute starting in Q3[6] - As of June 30, 2025, the company had $55 million in unfunded commitments available under its existing credit facilities[19] - The company maintains a healthy balance sheet with no net debt as of June 30, 2025[19] 2025 Guidance - Net revenue is projected to be between $271 million and $277 million, an increase from the previous guidance of $256 million to $265 million[22] - Adjusted EBITDA is expected to be between $59 million and $62 million, representing 22% of net revenue, an increase from the previous guidance of $55 million to $58 million[22]